Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG (Nasdaq: CRSP) generates frequent news as a gene editing biopharmaceutical company advancing CRISPR/Cas9-based medicines and related platforms. News coverage commonly highlights progress with CASGEVY, described as the world’s first approved CRISPR-based therapy for eligible sickle cell disease and transfusion-dependent beta thalassemia patients, along with updates on the company’s expanding in vivo and cell therapy pipeline.
Investors and observers following CRSP news can expect regular announcements on clinical trial data, such as Phase 1 and Phase 2 results for programs like CTX310 targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and zugo-cel (zugocaptagene geleucel) in autoimmune diseases and B-cell malignancies. Company press releases also report on regulatory milestones and commercialization developments for CASGEVY across multiple regions, including approvals, reimbursement agreements, and pediatric development plans.
CRISPR Therapeutics’ news flow also includes pipeline and platform updates for in vivo liver editing programs (CTX310, CTX320, CTX321, CTX340, CTX450), SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, and regenerative medicine efforts in Type 1 diabetes. Collaboration announcements with partners such as Vertex Pharmaceuticals, Sirius Therapeutics, and Lilly, as well as participation in major scientific and investor conferences, are additional recurring themes.
On Stock Titan’s CRSP news page, readers can review these press releases and third-party articles in one place, track how clinical, regulatory, and partnership developments evolve over time, and use this information as context when assessing CRISPR Therapeutics’ stock and long-term gene editing strategy.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two upcoming investor conferences in February 2023. The SVB Securities Global Biopharma Conference will take place on February 15, 2023, at 1:40 p.m. ET, followed by Citi’s 2023 Virtual Oncology Leadership Summit on February 22, 2023, at 1:00 p.m. ET. These sessions will feature live webcasts available on the company's website with replays accessible for 14 days post-event. CRISPR Therapeutics focuses on developing gene-based medicines for serious diseases using the CRISPR/Cas9 platform, establishing partnerships with companies like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) announced that its senior management will participate in B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 10:30 a.m. ET. The event will showcase the company's commitment to developing transformative gene-based therapies for serious diseases using its proprietary CRISPR/Cas9 platform. Interested parties can register for a live webcast or replay on the company's website under the 'Events & Presentations' section.
CRISPR Therapeutics (Nasdaq: CRSP) has appointed Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding has significant experience in biopharma, previously serving at Remix Therapeutics, where he was pivotal in raising over $150M and forming strategic collaborations. His expertise is expected to support CRISPR's growth and enhance its business development operations, as stated by CEO Samarth Kulkarni. CRISPR focuses on gene-based therapies utilizing its CRISPR/Cas9 platform for serious diseases.
CRISPR Therapeutics has provided an update from its Phase 1 CARBON trial for CTX110, a CAR T cell therapy targeting CD19+ B-cell malignancies. At the recent ASH Annual Meeting, data confirmed that CTX110 can lead to long-term complete remissions in heavily pre-treated Large B-cell Lymphoma patients, with three patients maintaining remission for over two years. The trial suggests a positive safety profile and beneficial effects of consolidation dosing, prompting the initiation of a Phase 2 registrational trial in collaboration with regulatory agencies.
Vertex Pharmaceuticals and CRISPR Therapeutics announced upcoming oral presentations of clinical data for exagamglogene autotemcel (exa-cel) at the 2022 ASH Annual Meeting. This investigational therapy targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Key presentations include efficacy and safety data from Phase 3 trials, with plans for regulatory submissions in the U.S., U.K., and EU by early 2023. The studies highlight the quality of life impacts for patients undergoing treatment.
Summary not available.
CRISPR Therapeutics (Nasdaq: CRSP) presented promising data on CTX130™, a CAR-T cell therapy targeting CD70 for relapsed renal cell carcinoma (RCC), showing a 77% disease control rate in heavily pretreated patients. The trial revealed a durable complete response in one patient, indicating potential for durable remissions. Additionally, preclinical findings on anti-CD83 CAR-T cells suggest their effectiveness against acute myeloid leukemia (AML). The ongoing development of next-generation CAR-Ts, including CTX131™, enhances their potency. These results could pave the way for innovative treatments in oncology.
CRISPR Therapeutics (Nasdaq: CRSP) announced a poster presentation on its investigational therapy CTX110® at the ASH 2022 Annual Meeting, scheduled for December 10-13, 2022. The poster will showcase preliminary results from the ongoing Phase 1 CARBON trial, which involves 32 patients with Large B-Cell Lymphoma (LBCL). Updates on the safety and efficacy of CTX110®, a gene-edited CAR-T therapy targeting CD19, will be highlighted. The study has received Regenerative Medicine Advanced Therapy designation from the FDA.
CRISPR Therapeutics (CRSP) reported its Q3 2022 financial results, highlighting a net loss of $174.5 million, an increase from $127.2 million in Q3 2021. Collaboration revenue fell to $0.1 million, down from $0.3 million the previous year. R&D expenses surged to $116.6 million, attributed to advancements in clinical programs. The company is advancing its gene-editing therapies, with multiple submissions expected for exa-cel, a therapy for sickle cell disease and beta thalassemia, with FDA review starting in November 2022.
CRISPR Therapeutics announced the resignation of its Chief Operating Officer, Lawrence Klein, effective year-end 2022, to pursue external opportunities. During his tenure, Klein significantly contributed to the company’s strategic direction and leadership. The company is currently searching for a successor while preparing for the regulatory filing of its lead program, exa-cel, with multiple other clinical programs also in progress. CEO Samarth Kulkarni expressed gratitude for Klein's contributions and highlighted the company's solid position for future success.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
